ABArshia Bhardwaj

Arshia Bhardwaj

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arshia Bhardwaj has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The impact of inflammatory bowel disease on women’s health: a cross-sectional study in India

    by Arshia Bhardwaj, Arshdeep Singh, Riya Sharma, Gopal Bhardwaj, Liza Joshi, Ramit Mahajan, Dharmatma Singh, Pankaj Kumar, Marla C. Dubinsky, Shaji Sebastian, et al.

    Background/Aims: The gender-specific impact of inflammatory bowel disease (IBD) on women in low- and middle-income countries remains underexplored. We aimed to assess the effects of IBD on different domains of women’s health.Methods: A cross-sectional study was conducted in women with IBD at a tertiary care center in North India. Women with IBD were interviewed using a structured questionnaire assessing menstrual, reproductive, sexual, mental, social, and financial health, and healthcare access.Results: Two hundred and two women (median age, 41 years; ulcerative colitis [n = 155, 76.7%]) were enrolled. Anemia was present in 161 women (79.7%), with a median hemoglobin of 10.5 g/dL. Among menstruating women (n = 138), 69 (50%) had irregular cycles, and 39 (28.3%) experienced IBD exacerbations during menstruation. Sexual dysfunction was reported in 82.5% (n = 137/166). Pregnancy-related concerns were common (n= 120, 59.4%), mainly due to risk of heritability and safety of IBD medication. Ten women (4.9%) attributed pregnancy loss to disease activity. Cervical cancer screening (3.0%) and human papillomavirus vaccination (4.0%) rates were low. The median SICC-IBD (social impact of chronic conditions in IBD) score was 0.6. Forty-three women (21.3%) reported difficulties in finding a partner due to IBD. Limited access to IBD specialists (n = 150, 74.3%) and medications (n = 164, 81.2%) were reported in hometown. Fifty-five women (27.2%) relied on loans to manage treatment expenses.Conclusions: IBD affects women across physical, reproductive, social, and financial domains. Culturally sensitive, multidisciplinary care models are essential to address these unmet needs.


  • Tofacitinib 20 vs 30 mg in acute severe ulcerative colitis: a double-blind randomized controlled trial

    by Arshdeep Singh, Aakash Garg, Arshia Bhardwaj, Dharmatma Singh, Aman Thakur, Lagandeep Kaur, Ankuriti Singla, Lavanya Kapoor, Ramit Mahajan, Varun Mehta, et al.

    Background & Aims: Tofacitinib has emerged as a promising therapy for acute severe ulcerative colitis (ASUC) due to its rapid onset of action. We compared the efficacy and safety of tofacitinib 20 mg/day vs 30 mg/day, both administered with intravenous corticosteroids (IVCS), in patients with ASUC. Methods: This was a double-blind, pilot, randomized controlled trial. Adult patients with ASUC were randomized to receive either tofacitinib 20 mg/day (Group 1) or 30 mg/day (Group 2) along with IVCS (hydrocortisone, 100 mg IV every 6 hours). The primary endpoint was clinical response by day 7. The secondary outcome was the cumulative probability of medical rescue therapy or post discharge escalation of therapy or colectomy within 90 days. Results: Seventy-two patients were randomized, with 36 allocated to each treatment group. At day 7, clinical response was achieved in 33/36 (91.7%) patients in Group 1 and 31/36 (86.1%) in Group 2(RR 1.06, 95% CI 0.90-1.25; P = .46). The absolute difference in response rates was 5.6% (95% CI −9.98% to 21.34%). Rescue therapy was required in 3 patients in Group 1 (all received infliximab) and 5 patients in Group 2 (2 underwent colectomy and 3 received infliximab). Event-free survival at 90 days, defined as the absence of rescue therapy, treatment escalation, or colectomy, was similar between groups (83.3% vs 80.2%; log-rank P = .74). Adverse events were predominantly mild, with no reported venous thromboembolism or major adverse cardiovascular events. Conclusions: In this exploratory pilot trial, no statistically significant differences were observed with tofacitinib 30 mg/day compared with 20 mg/day when administered with IVCS. Clinical trial registration number: Clinical Trials Registry-India: CTRI/2024/10/075098

  • Diagnostic accuracy of the international bowel ultrasound segmental activity score for assessing disease activity in Crohn’s disease

    by Ashanpreet Kaur, Arshdeep Singh, Arshia Bhardwaj, Saurabh Singla, Suryaveer Singh, Vikram Narang, Ashutosh Bawa, Harmeet Kaur, Riya Sharma, Ramit Mahajan, et al.


  • Open Access

    Exploring the rationale for upfront corticosteroid–JAK inhibitor combination therapy in acute severe ulcerative colitis

    by Arshdeep Singh, Arshia Bhardwaj, Vandana Midha, Laurent Peyrin-Biroulet, Ajit Sood


  • Open Access

    Tofacitinib 20 mg Versus 30 mg in Acute Severe Ulcerative Colitis: A Double-Blind Randomized Controlled Trial

    by Arshdeep Singh, Aakash Garg, Arshia Bhardwaj, Dharmatma Singh, Aman Thakur, Lagandeep Kaur, Ankuriti Singla, Lavanya Kapoor, Ramit Mahajan, Varun Mehta, et al.

    Background: In acute severe ulcerative colitis (ASUC), the combination of tofacitinib with intravenous corticosteroids (IVCS) has been shown to improve treatment response and reduce the need for rescue therapy, as demonstrated in the TACOS trial; however, the optimal dose of tofacitinib in ASUC remains poorly defined.Methods: This was a single-center, double-blind, randomized controlled trial. Adult patients with ASUC were randomized in a 1:1 ratio to receive either tofacitinib 20 mg/day (Group 1) or 30 mg/day (Group 2) along with IVCS (hydrocortisone, 100 mg IV every 6 hours). The primary endpoint was clinical response by day 7, defined as a reduction in the Lichtiger Colitis Activity Index by more than 3 points with an absolute score <10 for two consecutive days without the need for rescue therapy. The key secondary outcome was the cumulative probability of medical rescue therapy or post discharge escalation of therapy or colectomy within 90 days.Results: A total of 72 patients were randomized (36 per group). At day 7, clinical response was achieved in 33/36 (91.7%) patients in Group 1 and 31/36 (86.1%) in Group 2 (RR 1.06, 95% CI 0.90–1.25; p=0.46). The absolute difference in response rates was 5.6% (95% CI -9.98% to 21.34%). Rescue therapy was required in 3 patients in Group 1 (all received infliximab) and 5 patients in Group 2 (2 underwent colectomy and 3 received infliximab). Event-free survival at 90 days, defined as the absence of rescue therapy, treatment escalation, or colectomy, was similar between groups (83.3% vs 80.2%; log-rank p = 0.74). Adverse events were predominantly mild, with no reported venous thromboembolism or major adverse cardiovascular events.Conclusion: In this exploratory pilot trial, no statistically significant difference was observed with tofacitinib 30 mg/day compared with 20 mg/day when administered with IVCS. Given the limited sample size and exploratory design, larger adequately powered trials are required.

  • Exclusive enteral nutrition for induction of remission in Crohn’s disease in adults: A systematic review and meta-analysis of randomized trials and real-world studies

    by Kirandeep Kaur, Arshdeep Singh, Simrat Kaur, Riya Sharma, Sanya Malik, Arshia Bhardwaj, Anuraag Jena, Ramit Mahajan, Vandana Midha, Ajit Sood

    Background Exclusive enteral nutrition (EEN) is an established induction therapy in pediatric Crohn’s disease (CD); however, its role in adults remains less well defined. Methods A systematic search was performed through December 2025. Eligible studies included randomized controlled trials (RCTs) and non-randomized studies evaluating EEN in adults (≥ 18 years) with active CD. The primary outcome was clinical remission, defined by validated disease activity indices. Risk of bias was assessed using RoB 2 and the Newcastle–Ottawa Scale. Random-effects models were applied to estimate pooled remission rates and relative risks. Results Forty studies, comprising 2459 patients, were included. In 23 real-world cohort studies (n = 1269), the pooled clinical remission rate with EEN was 66% (95% CI = 0.60-0.71, I2 = 69.9%, p < 0.0001). In five RCTs (n = 315) comparing corticosteroids with EEN, corticosteroids achieved higher remission rates compared with EEN (RR 0.65, 95% CI = 0.50–0.84; p = 0.0009). In eight RCTs (n = 301), remission rates did not differ significantly between elemental and non-elemental formulations (RR 1.04, 95% CI = 0.88–1.23). Sub-group analyses by protein type and lipid composition showed no differences in efficacy. In two studies, combination therapy with biologics plus EEN was associated with a higher clinical remission compared with biologics alone (RR 0.75; 95% CI = 0.67–0.84; p < 0.0001). Adverse events were generally mild, with poor palatability being most frequent. Conclusion EEN induces clinical remission in adults with CD. It is less efficacious than corticosteroids to induce clinical remission. The efficacy of EEN is independent of formula composition. Given its favorable safety profile, EEN may represent a therapeutic option in select adult patients. PROSPERO registration number: CRD42023445039 Graphical Abstract The alternative text for this image may have been generated using AI.


  • Open Access

    Partial responders to intravenous corticosteroids at day 3 benefit from continued therapy in acute severe ulcerative colitis

    by Arshdeep Singh, Arshia Bhardwaj, Riya Sharma, Dharmatma Singh, Devanshi Jain, Namita Bansal, Shaji Sebastian, Laurent Peyrin-Biroulet, Vandana Midha, Ajit Sood

    In acute severe ulcerative colitis (ASUC), early response patterns to intravenous corticosteroids (IVCS) during the first week may shape subsequent disease course. Characterizing these trajectories is crucial for guiding timely therapy and improving patient outcomes. We evaluated response patterns to IVCS in hospitalized patients with ASUC. Clinical response was categorized as complete response (CR), partial response (PR), or non-response (NR) on days 3, 5, and 7. Patients were followed up to day 90 for need for rescue therapy (RT), post-discharge escalation of therapy (EOT), and mortality. Seventy-nine patients were analyzed. By day 3, 12 (15%) achieved CR, 34 (43%) PR, and 33 (42%) NR. Among the 67 patients with PR or NR on day 3, 9 (13.4%) achieved CR by day 5 and 22 (32.8%) more by day 7. On day 7, CR, PR, and NR were observed in 42 (53%), 17 (21%), and 20 (25%) patients, respectively. Patients with CR on day 3 had a lower, but not statistically significant, likelihood of needing RT + EOT by day 90 compared to NR (29% vs. 47%; p = 0.15). However, by day 5, patients with CR or PR had significantly lower day 90 RT + EOT needs compared to NR (26% vs. 54%, p = 0.02; 23% vs. 54%, p = 0.03). By day 7, the day 90 probability of RT + EOT was higher in PR (45%) and NR (63%) versus CR (16%) (p = 0.001 and < 0.0001, respectively). Only a small proportion of patients with ASUC show CR at day 3; most are partial responders. Partial responders to IVCS at day 3 frequently achieve CR by day 5–7, and have relatively favorable short term disease course, highlighting the prognostic value of early response stratification.


  • Open Access

    Clinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India

    by Arshdeep Singh, Mayur Luthra, Arshia Bhardwaj, Ramit Mahajan, Riya Sharma, Dharmatma Singh, Devanshi Jain, Omesh Goyal, Varun Mehta, Kirandeep Kaur, et al.

    Background/Aims: Acute severe ulcerative colitis (ASUC) is a time-critical situation requiring urgent intervention. Limited data exist on the evolving clinical spectrum of ASUC in the era of advanced therapies. Methods: This prospective real-world observational cohort study included 145 adult patients hospitalized with ASUC between January 2020 and June 2024. ASUC was defined by the modified Truelove and Witts criteria. Demographics and disease characteristics, including disease severity, probable precipitating factors, and corticosteroid failure rates, were recorded. Results: The median age of patients was 36 years (interquartile range, 26–48.5 years) with 63 females (43.4%). Most patients had left-sided colitis (53.1%). The median disease duration was 1 year (IQR, 0.5–3 years), with 91 patients (62.7%) presenting with ASUC within the first year of diagnosis of ulcerative colitis. One-third of the patients had previous exposure to biologics and small molecules. The most commonly reported probable precipitants of ASUC were poor compliance with treatment (n = 43, 29.6%), antibiotic use (n = 35, 24.1%), high perceived stress (n = 32, 22.1%), and Clostridioides difficile infection (n = 19, 13.1%). Forty patients (27.5%) were non-responders to intravenous corticosteroids (IVCS). Twenty-nine patients (20%) received medical rescue therapy (infliximab, n = 14 [48.27%], cyclosporine A, n = 6 [20.68%], and tofacitinib, n = 9 [31.03%]). Seven patients (4.82%; 4 after non-response to IVCS and 3 after non-response to medical rescue therapy) underwent colectomy. Conclusions: In this cohort of ASUC patients, poor treatment compliance, antibiotic use, stress, and C. difficile infection were common precipitants of flare-ups. Nearly one-third of patients required medical rescue therapy, and a small proportion ultimately underwent colectomy.


  • Open Access

    Deciphering the diet-inflammatory bowel disease relationship: knowledge gaps and future perspectives

    by Arshdeep Singh, Arshia Bhardwaj, Vandana Midha, Ajit Sood

    Deciphering the diet-inflammatory bowel disease relationship: knowledge gaps and future perspectives